Antibacterial activity of teicoplanin against Clostridium difficile

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 27, Issue 3, 1996, Pages 606-609

  Wongwanich, Siripan ^a   Kusum, Mayura ^a   Phan Urai, Ratanasuda ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTITRICHOMONAL AGENT; CLINDAMYCIN; METRONIDAZOLE; TEICOPLANIN; VANCOMYCIN;

ARTICLE; CLOSTRIDIUM DIFFICILE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; IN VITRO STUDY; MICROBIOLOGICAL EXAMINATION;

ANTI-BACTERIAL AGENTS; ANTITRICHOMONAL AGENTS; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE; DOSE-RESPONSE RELATIONSHIP, DRUG; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; TEICOPLANIN; VANCOMYCIN;

EID: 0030225147     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Babul N, Pasko M. Teicoplanin: A new glycopeptide antibiotic complex. Drug Itell Clin Pharm 1988; 22 : 218-26.
2. Bartlett JG. Treatment of Clostridium difficile colitis. Gastroenterology 1985; 89 : 1192-5.
3. Barlett JG. Treatment of Clostridium difficile colitis. Gastroenterology 1985; 89 : 1192-5.
4. Barlett JG, Tedesco FJ, Shull S, Lowe B, Chang T. Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology 1980; 78 : 431-4.
5. Bartoloni A, Colao MG, Orsi A, Dei R, Giganti E, Parenti F. In vitro activity of vancomycin teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile. J Antimicrob Chemother 1990; 26 : 627-33.
6. Cappell M, Philogene C. Clostridium difficile infection is a treatable cause of diarrhea in patients with advanced human immunodeficiency virus infection: a study of seven consecutive patients admitted from 1986 to 1992 in a university teaching hospital. Am J Gastroenterol 1993; 88 : 891-7.
7. Citron DM, Ostovari MI, Kasrlsson A, Goldstein E. Evaluation of the E test for susceptibility testing of anaerobic bacteria. J Clin Microbiol 1991; 29 : 2197-2203.
8. Chang T, Gorbach L, Bartlett JG, Saginur R. Bacitracin treatment of antibiotic-associated colitis and diarrhea caused by Clostridium difficile toxin. Gastroenterology 1980; 78 : 1584-6.
9. Cozart JC, Kalangi SS, Clench MH, et al. Clostridium difficile diarrhea in patients with AIDS versus non-AIDS controls. J Clin Gastroenterol 1993; 16 : 192-4.
10. De Lalla F, Nicolin R, Rinaldi E, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 1992; 36 : 2192-6.
11. Finegold SM. Susceptibility testing of anaerobic bacteria. J Clin Microbiol 1988; 26 : 1253-6.
12. Holdeman LV, Cato EP, Moore WEC, eds. Anaerobic laboratory manual. 4th ed. Blackburg, Virginia: Virginia Polytechnic Institute and State University, 1977.
13. Jorgensen JH, Howell AW, Maher LA. Quantitative antimicrobial susceptibility testing of Haemophilus influenzae and Streptococcus pneumoniae by using the E test. J Clin Microbiol 1991; 29 : 109-14.
14. Kusum M, Wongwanich S. Susceptibility of Clostridium difficile to sixteen antimicrobial agents. J Health Sci 1994; 3 : 255-61.
15. National Committee for Clinical Laboratory Standards (NCCLS) Document M100-S 5 1994; 14 : M7-A3.
16. Newsom SW, Matthews J, Rampling AM. Susceptibility of Clostridium difficile strains to new antibiotics: quinolones, efrotomycin, teicoplanin and imipenem. J Antimicrob Chemother 1985; 15 : 648-50.
17. Phan-Urai R, Wongwanich S, Kusum M. Evaluation of the leucine arylamidase activity to identification of Clostridium difficile. J Med Tech Assoc Thai 1994; 23 : 35-9.
18. Sheikh W, Pitkin DH, Nadler H. Antibacterial activity of meropenem and selected comparative agents against anaerobic bacteria at seven North America Centers. Clin Infect Dis 1993; 16 (suppl 4) : S361-6.
19. Stille W, Sietzen W, Dieterich HA, Fell JJ. Clinical efficacy and safety of teicoplanin. J Antimicrob Chemother 1988; 21 (suppl A) : 69-79.
20. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhea and colitis. Lancet 1983; 2 : 1043-6.
21. Verbist L, Tjandramaga B, Aahendrickx B, et al. In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob Agents Chemother 1984; 26 : 881-6.
22. Walters BAJ, Robert SR, Stafford R, Senevirarne E. Relapse of antibiotic associated colitis: endogenous persistence of Clostridium difficile during vancomycin therapy. Gut 1983; 24 : 206-12.
23. Wilcox MH, Spencer RC. Clostridium difficile infection: responses, relapses and reinfections. J Hosp Infect 1992; 22 : 85-92.
24. Wistrom J, Lundholm R, Prag M, et al. Treatment of Clostridium difficile associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. Scand J Infect Dis 1994; 26 : 309-16.
25. Wongwanich S, Ramsiri S, Vanasin B, Khowsaphit P, Tantipatayangkul P, Phan-urai R. Clostridium difficile-associated diseases in Thailand. Southeast Asian J Trop Med Public Health 1990; 20 : 367-72.